Điều trị tăng liều Imatinib trên bệnh nhân u mô đệm đường tiêu hoá giai đoạn muộn tiến triển sau điều trị bước 1 liều chuẩn

Abstract

Objective: Evaluating the result of high-dose imatinib for metastatic gastrointestinal stromal tumours after failure standard-dose first line. Patients and method: Restrospective analysis of 46 patients with metastatic gastrointestinal stromal tumours after failure standard-dose imatinib treated with high-dose imatinib at K hospital from 1/2015 đến 10/2019. Results: Median age was 54.6±9.5, male was 58.7%. The common primary tumor was gastric tumor. The mean time to failure of imatinib standard-dose 400mg/day was 38.2±5.3 months. Liver lesions were the most common lesions progressed after imatinib standard-dose failure (71.7%), primary tumor progressed was 39.1%. There was no patient who had complete response with treatment, the proportion of partial response accounted for 21.7% and stable disease was 45.7%. The clinical benefit rate was 67.4%. The sex-female, primary gastric tumor, good ECOG performance status, neutrophils, hemoglobine and albumin before treatment were the significant prognostic factors affecting the treatment response, p <0.05. The mean time to failure was 22.5 ± 3.4 (months), (min: 2.0; max: 58.0), median was 11.0 months. Conclusion: Treatment of high-dose imatinib after failure standard-dose 400mg/day showed the efficacy and good tolerance in metastatic GISTs.